GSK halts camlipixant development for chronic cough after mixed results
Go back to GSK halts camlipixant development for chronic cough after mixed results| GLAXOSMITHKLINE PLC (NYSE: GSK) | Delayed: 51.08 +0.86 (1.71%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $50.22 | 52 Week High | $45.58 | |||
| Open | $50.75 | 52 Week Low | $37.82 | |||
| Day High | $51.32 | P/E | N/A | |||
| Day Low | $50.46 | EPS | $0.00 | |||
| Volume | 2,870,314 | |||||
